1800 EL CAMINO REAL, SUITE D, MENLO PARK, CA
Stock Option Repricing Approved for Executive Officers at AN2 Therapeutics
Reports Fourth Quarter and Full Year End 2025 Financial Results and Recent Business and Scientific Highlights
Announces $40 Million Private Placement Financing
Appointment of Sarah Williams as VP, Controller and Principal Accounting Officer
Reports Third Quarter 2025 Financial Results and Recent Business and Scientific Highlights
Reports Second Quarter 2025 Financial Results and Recent Business and Scientific Highlights
News, Securities Holder Rights or Indentures
Investor Presentation
FY 2025
Q3
Q2
Q1
FY 2024
Notice of Exempt Offering of Securities
Registration Statement for Securities to be Offered to Employees
Registration of Securities
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Definitive Proxy Statement
Additional Proxy Materials
PRE 14A
Statement of Changes in Beneficial Ownership